<code id='5A5DB2CBBB'></code><style id='5A5DB2CBBB'></style>
    • <acronym id='5A5DB2CBBB'></acronym>
      <center id='5A5DB2CBBB'><center id='5A5DB2CBBB'><tfoot id='5A5DB2CBBB'></tfoot></center><abbr id='5A5DB2CBBB'><dir id='5A5DB2CBBB'><tfoot id='5A5DB2CBBB'></tfoot><noframes id='5A5DB2CBBB'>

    • <optgroup id='5A5DB2CBBB'><strike id='5A5DB2CBBB'><sup id='5A5DB2CBBB'></sup></strike><code id='5A5DB2CBBB'></code></optgroup>
        1. <b id='5A5DB2CBBB'><label id='5A5DB2CBBB'><select id='5A5DB2CBBB'><dt id='5A5DB2CBBB'><span id='5A5DB2CBBB'></span></dt></select></label></b><u id='5A5DB2CBBB'></u>
          <i id='5A5DB2CBBB'><strike id='5A5DB2CBBB'><tt id='5A5DB2CBBB'><pre id='5A5DB2CBBB'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:76
          Aduhelm package
          Jessica Rinaldi/The Boston Globe

          Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

          Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

          advertisement

          “When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Congress may force more Covid
          Congress may force more Covid

          HouseOversightChairmanBradWenstrup(R-Ohio)AnnaMoneymaker/GettyImagesTheHealthandHumanServicesDepartm

          read more
          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more

          Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

          INAFASSBENDER/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup tog